Abiopharma

JYONG BIOTECH LTD. (MENS)

Symbol	MENS
Name	JYONG BIOTECH LTD.
Sector	HEALTH CARE
Region	Asia
Industry	Biotechnology: Pharmaceutical Preparations
Address	23F-3, NO. 95, SECTION 1, XINTAI 5 TH ROAD,XIZHI DISTRICT,XIZHI DISTRICT, NEW TAIPEI CITY, 221, Taiwan
Telephone	(8862) 27325205
Fax	—
Email	—
Website	—
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001954488
Description	Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan. Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis. Additional info from NASDAQ: Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan. Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.

2026-05-15 12:30

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

2026-04-29 14:12

New Form NT 20-F - Jyong Biotech Ltd. Filed: 2026-04-29 AccNo: 0001213900-26-049070 Size: 31 KB

2026-04-28 12:30

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

2026-04-24 16:06

New Form SCHEDULE 13D - Jyong Biotech Ltd. Filed: 2026-04-24 AccNo: 0001213900-26-047468 Size: 25 KB

2026-04-14 12:46

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-14 AccNo: 0001096906-26-000531 Size: 3 KB

2026-04-08 11:12

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-08 AccNo: 0001096906-26-000502 Size: 5 KB

2026-04-01 16:44

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-01 AccNo: 0001096906-26-000465 Size: 4 KB

2026-04-01 16:34

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-01 AccNo: 0001096906-26-000463 Size: 4 KB

2026-04-01 16:21

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-01 AccNo: 0001096906-26-000462 Size: 4 KB

2026-04-01 16:10

New Form 3 - Jyong Biotech Ltd. Filed: 2026-04-01 AccNo: 0001096906-26-000460 Size: 3 KB

No clinical trials found for this company.

No clinical products found for this company.